ClinicalBiostats

Clinical Trials

See the methods at work.

Statistical analyses of real clinical trials: design, endpoints, results and interpretation, organized by therapeutic area and linked to the methods behind them.

407 trials analyzed so far

Trials that use: Cox proportional-hazards model

New to this method? Read the tutorial →

118 results

SIGNIFYIndependent statistical analysis of SIGNIFY (NCT02446990), a randomized phase 3 trial of ivabradine versus placebo in patients with stable coronary artery disease without clinical heart failure, including Cox proportional-hazards analyses and interpretation…Phase 3Results postedn = 19,102NCT02446990
SOCRATESIndependent statistical analysis of the SOCRATES phase 3 trial of ticagrelor versus acetylsalicylic acid after acute ischaemic stroke or transient ischaemic attack, including endpoint definitions, Cox and logistic regression methods, efficacy results,…Phase 3Results postedn = 13,307NCT01994720
SOLO1Complete statistical analysis of SOLO1, a randomized phase 3 trial of olaparib maintenance monotherapy versus placebo in BRCA-mutated advanced ovarian cancer following first-line platinum-based chemotherapy.Phase 3Results postedn = 450NCT01844986
SOLOIST-WHFIndependent statistical analysis of SOLOIST-WHF (NCT03521934), evaluating sotagliflozin versus placebo in participants with type 2 diabetes and worsening heart failure. Includes trial design, registered endpoints, Cox, ANCOVA and MMRM methodology, reported results,…Phase 3Results postedn = 1,222NCT03521934
SONARIndependent statistical analysis of the phase 3 SONAR trial of atrasentan versus placebo in diabetic nephropathy, including the composite renal endpoint, hazard ratios, confidence intervals, p-values, trial design, and statistical methodology.Phase 3Results postedn = 5,107NCT01858532
STRENGTHComplete statistical analysis of the STRENGTH phase 3 trial of Epanova versus corn oil control in high cardiovascular risk patients with hypertriglyceridemia, including trial design, MACE, Cox proportional-hazards analysis, secondary endpoints, safety,…Phase 3Results postedn = 13,078NCT02104817
SWOG 9346Independent statistical analysis of SWOG 9346, a randomized phase 3 trial of intermittent versus continuous hormonal therapy in men with stage IV prostate cancer, including overall survival and 3-month functional outcomes.Phase 3Results postedn = 3,040NCT00002651
TAILORxIndependent statistical analysis of the TAILORx phase 3 trial, focusing on 5-year disease-free survival, the Cox proportional-hazards model, hazard ratios, confidence intervals, and the trial's noninferiority design.Phase 3Results postedn = 10,273NCT00310180
TDF2Independent statistical analysis of the randomized TDF2 trial of tenofovir disoproxil fumarate plus emtricitabine for HIV prevention, including trial design, registered endpoints, Cox and logistic regression methods, reported results, safety, limitations, and…Phase 2/3Results postedn = 1,219NCT00448669
TECOSComplete statistical analysis of TECOS, the randomized phase 3 study of sitagliptin versus placebo in type 2 diabetes mellitus, including non-inferiority analysis of MACE plus, Cox proportional-hazards methodology, secondary endpoints, safety, and…Phase 3Results postedn = 14,671NCT00790205
THALESComplete statistical analysis of the phase 3 THALES trial of ticagrelor versus placebo in acute ischaemic stroke and transient ischaemic attack, including trial design, endpoints, Cox and logistic regression methods, efficacy results,…Phase 3Results postedn = 11,016NCT03354429
THEMISIndependent statistical analysis of THEMIS, a randomized phase 3 trial of ticagrelor 60 mg versus placebo in patients with type 2 diabetes mellitus, including time-to-event methods, hazard ratios, confidence intervals, safety analyses,…Phase 3Results postedn = 19,271NCT01991795
TRA 2P-TIMI 50Independent statistical analysis of TRA 2P-TIMI 50 (NCT00526474), including randomized trial design, time-to-event endpoints, Cox proportional-hazards methods, efficacy results, bleeding outcomes, post-hoc analyses, and statistical interpretation.Phase 3Results postedn = 26,449NCT00526474
TROPION-Breast01Independent statistical analysis of TROPION-Breast01, evaluating Dato-DXd versus investigator's choice of chemotherapy in participants with inoperable or metastatic HR-positive, HER2-negative breast cancer.Phase 3Results postedn = 732NCT05104866
VICTORIAIndependent statistical analysis of the VICTORIA phase 3 trial of vericiguat versus placebo in participants with heart failure with reduced ejection fraction, including trial design, time-to-event endpoints, hazard ratios, confidence intervals, safety,…Phase 3Results postedn = 5,050NCT02861534
VISIONIndependent statistical analysis of the VISION phase 3 trial of 177Lu-PSMA-617 plus best supportive/best standard of care in metastatic castrate-resistant prostate cancer, including randomized design, time-to-event endpoints, hazard ratios, response analyses, safety,…Phase 3Results postedn = 861NCT03511664
VOICEIndependent statistical analysis of the VOICE phase 2 trial of tenofovir 1% gel, oral tenofovir disoproxil fumarate, and emtricitabine/tenofovir disoproxil fumarate for prevention of HIV infection in women.Phase 2Results postedn = 5,029NCT00705679
ZUMA-7Independent statistical analysis of ZUMA-7, the randomized phase 3 trial of axicabtagene ciloleucel versus standard of care therapy in relapsed/refractory diffuse large B-cell lymphoma, including event-free survival, response, overall survival, quality of…Phase 3Results postedn = 359NCT03391466